The G4X Spatial Sequencer is a high-throughput in situ sequencing platform. With simultaneous transcriptomic, proteomic, and fH&E analysis from FFPE samples, the G4X is a high-impact multiomic platform for cost-effective single-cell cancer research.
Generate powerful multiomic data from your samples with in situ sequencing and imaging on the G4X Spatial Sequencer. Three recipients of the G4X Research Grant will receive $50,000 of spatial sequencing services, good for 40cm2 of imaging or applicable to a larger project. Recipients also eligible to recieve a travel grant to present the data at a conference.
Important Dates
Application Opens
Application Closes
Grants Awarded
Want to access tomorrow’s high-throughput in situ sequencing technology today with cost-effective subcellular spatial multiomic services for your cancer research studies? Meet our team of experts and get involved today.
Demo the G4X, see the data, and meet our team of experts in San Diego at American Association for Cancer Research (AACR) 2024 to learn more about how the G4X can transform your research.
Drew founded Singular Genomics in 2016 serving as the CEO and Chairman. Drew is a serial entrepreneur and venture investor in the biotech industry and has been involved in the founding of several successful companies. Prior to Singular Genomics, Drew founded Truvian Sciences, a low volume blood testing technology aimed at making routine blood tests easier, less invasive, and more affordable. Drew was also involved in the founding of Aspen Neurosciences where he co-led the seed financing and helped assemble a world-class team to combat Parkinson’s Disease using a patient’s own stem cells. Drew was also a seed investor and held an operating role in Edico Genome which sold to Illumina in 2018.
Drew received an MBA from the Rady School of Management at the University of California, San Diego and a BA in Political Science and International Relations from the University of California, San Diego.
